Literature DB >> 15155234

In vitro activity of OPT-80 against Clostridium difficile.

Grit Ackermann1, Birgit Löffler, Daniela Adler, Arne C Rodloff.   

Abstract

Clostridium difficile remains the major cause of nosocomial diarrhea. Reports on impaired susceptibility of C. difficile to metronidazole and vancomycin and frequent relapses of patients after therapy necessitate the search for new substances. With this study, the activity of OPT-80, a new macrocycle, against 207 C. difficile strains and against other obligately anaerobic bacteria was tested. OPT-80 showed high in vitro activity against all C. difficile strains tested.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15155234      PMCID： PMC415632          DOI： 10.1128/AAC.48.6.2280-2282.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Reduced susceptibility of Clostridium difficile to metronidazole.

Authors:  J S Brazier; W Fawley; J Freeman; M H Wilcox
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

2.  Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains.

Authors:  S S Jang; L M Hansen; J E Breher; D A Riley; K G Magdesian; J E Madigan; Y J Tang; J Silva; D C Hirsh
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

3.  Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

Authors:  S S Wong; P C Woo; W K Luk; K Y Yuen
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

4.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Authors:  Lorraine Kyne; Mary Beth Hamel; Rajashekhar Polavaram; Ciarán P Kelly
Journal:  Clin Infect Dis       Date:  2001-12-17       Impact factor: 9.079

6.  Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.

Authors:  R Fekety; L V McFarland; C M Surawicz; R N Greenberg; G W Elmer; M E Mulligan
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

7.  Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

Authors:  R J Theriault; J P Karwowski; M Jackson; R L Girolami; G N Sunga; C M Vojtko; L J Coen
Journal:  J Antibiot (Tokyo)       Date:  1987-05       Impact factor: 2.649

8.  Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action.

Authors:  S Sergio; G Pirali; R White; F Parenti
Journal:  J Antibiot (Tokyo)       Date:  1975-07       Impact factor: 2.649

9.  In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.

Authors:  R N Swanson; D J Hardy; N L Shipkowitz; C W Hanson; N C Ramer; P B Fernandes; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

10.  Recurrent Clostridium difficile disease: epidemiology and clinical characteristics.

Authors:  L V McFarland; C M Surawicz; M Rubin; R Fekety; G W Elmer; R N Greenberg
Journal:  Infect Control Hosp Epidemiol       Date:  1999-01       Impact factor: 3.254
  10 in total
  32 in total

1.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

3.  In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.

Authors:  Sydney M Finegold; Denise Molitoris; Marja-Liisa Vaisanen; Yuli Song; Chengxu Liu; Mauricio Bolaños
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors:  Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal:  Antimicrob Agents Chemother       Date:  2008-02-11       Impact factor: 5.191

6.  In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.

Authors:  James A Karlowsky; Nancy M Laing; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

7.  Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile-Associated Diarrhea in Adults.

Authors:  Martin Paspe Cruz
Journal:  P T       Date:  2012-05

Review 8.  Clostridium difficile infection: management strategies for a difficult disease.

Authors:  Sahil Khanna; Darrell S Pardi
Journal:  Therap Adv Gastroenterol       Date:  2014-03       Impact factor: 4.409

9.  OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Authors:  Thomas J Louie; Judy Emery; Walter Krulicki; Brendan Byrne; Manuel Mah
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

Review 10.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.